透過您的圖書館登入
IP:3.146.221.52
  • 期刊
  • OpenAccess

Chemotherapy induced anemia in patients with malignant diseases: A Montenegro study

並列摘要


Aims: Oncology patients treated by chemotherapy (CT) often develop different levels of anemia. We analyzed efficacy and safety of three times weekly administration of epoetin beta in hematologic and solid tumors in Montenegro. Methods: One hundred and twenty anemic patients with solid tumors (75 patients) and non-myeloid hematological malignancies (45 patients) were treated with epoetin beta in the period from January 2009 till May 2012. We analyzed efficacy in terms of hemoglobin (Hb) level, transfusion requirement, dosing schedule and safety in this open label, single arm, noninterventional study. Anemic patients with Hb level <11 g/dL, treated with chemotherapy were included in this first multicentre oncology study in Montenegro. Statistical multivariate analysis method was used. Results: In our study, most of patients had moderate anaemia, while 5.8% had severe level. Statistical significance was found in level of Hb during epoetin beta therapy compare to baseline and other study visits (p = 0.01). The percentage of patients with normal Hb values was increasing during the treatment. The need for blood transfusion was decreasing during epoetin beta therapy (first visit 8.3%, fifth visit 1.7%). Majority of patients (68%) did not report any adverse event. Two patients had thromboembolic events. Conclusion: Administration of epoetin beta 30.000 IU three times weekly significantly increased Hb levels in anemic patients with different solid tumors and non-myeloid hematological malignancies who were receiving chemotherapy. The number of required transfusion is decreasing during the study treatment. Therapy with epoetin beta was well tolerated. Benefits of using epoetin beta were confirmed in patients with chemotherapy induced anemia.

並列關鍵字

Anemia cancer chemotherapy epoetin beta safety

延伸閱讀